RGLS-8429 is an antisense rnai oligonucleotide commercialized by Regulus Therapeutics, with a leading Phase I program in Polycystic Kidney Disease. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RGLS-8429’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for RGLS-8429 is expected to reach an annual total of $139 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RGLS-8429 is under development for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The therapeutic candidate acts by targeting microRNA-17 (miR-17). It is being developed based on microRNA platform technology. The platform involves single-stranded oligonucleotides which regulate the expression of genes. It is administered through subcutaneous route.
Regulus Therapeutics Overview
Regulus Therapeutics (Regulus) is a biopharmaceutical company that focuses on the discovery and development of microRNA-based therapeutics for orphan kidney diseases such as autosomal dominant polycystic kidney diseases. It is investigating RG-012 which is a chemically modified oligonucleotide that inhibits the function of miR-21 for the treatment of Alport syndrome and RGLS8429 targeting autosomal dominant polycystic kidney disease (ADPKD). The company is also evaluating therapies against infectious diseases and central nervous system disorders. It utilizes its proprietary microRNA development platform to discover and develop its therapies for cancer, fibrosis, metabolic and inflammatory disorders. Regulus Therapeutics is headquartered in San Diego, California, the US.
The operating loss of the company was US$27.8 million in FY2021, compared to an operating loss of US$14.2 million in FY2020. The net loss of the company was US$27.8 million in FY2021, compared to a net loss of US$15.7 million in FY2020.
For a complete picture of RGLS-8429’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.